Research compounds
Tesofensine
Monoamine Reuptake Inhibitor
Originally developed as a treatment for Parkinson's and Alzheimer's, but unexpectedly caused significant weight loss in trials. Now being pursued as an anti-obesity agent.
Also known as: NS2330, teso
- Status
- Tesofensine is in Phase 3 clinical trials and not approved.
- Evidence
- Human trials. Published clinical trials in people report results.
- Half-life
- ~220 hours (~9 days)
- How it's taken
- Daily oral capsule
- Mechanism
- Metabolic (non-incretin)
How Tesofensine works
Inhibits the reuptake of three neurotransmitters — serotonin, dopamine, and norepinephrine — in the brain. This triple action reduces appetite, increases energy expenditure, and enhances feelings of satiety and reward from eating less.
What research has looked at
- Significant weight loss reported in phase 2 trials
- Reduces appetite through brain chemistry
- Increases metabolic rate
- Oral dosing
- May improve mood alongside weight loss
Evidence level: Human trials. Published clinical trials in people report results. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Increased heart rate
- Dry mouth
- Insomnia
- Constipation
- Mood changes
- Potential cardiovascular concerns
- Not FDA-approved
Sources
- Active clinical trials for tesofensine · U.S. National Library of Medicine
- PubMed research on tesofensine monoamine reuptake obesity · NIH · National Library of Medicine
- DrugBank record for tesofensine · DrugBank
Track Tesofensine in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Tesofensine FAQ
What is Tesofensine?
Originally developed as a treatment for Parkinson's and Alzheimer's, but unexpectedly caused significant weight loss in trials. Now being pursued as an anti-obesity agent.
How does Tesofensine work?
Inhibits the reuptake of three neurotransmitters — serotonin, dopamine, and norepinephrine — in the brain. This triple action reduces appetite, increases energy expenditure, and enhances feelings of satiety and reward from eating less.
Is Tesofensine FDA approved?
No. Tesofensine is in Phase 3 clinical trials and not approved. Evidence level: human trials. Published clinical trials in people report results.
What is the half-life of Tesofensine?
Reported half-life: ~220 hours (~9 days).
How is Tesofensine taken?
Daily oral capsule.
What side effects have been reported with Tesofensine?
Reported in the sources: Increased heart rate; Dry mouth; Insomnia; Constipation; Mood changes; Potential cardiovascular concerns; Not FDA-approved.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.